Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33158488" target="_blank" >RIV/61989592:15310/15:33158488 - isvavai.cz</a>
Result on the web
<a href="http://www.tandfonline.com/doi/abs/10.1517/13543776.2015.1056737?journalCode=ietp20#.VuFHCvnhC70" target="_blank" >http://www.tandfonline.com/doi/abs/10.1517/13543776.2015.1056737?journalCode=ietp20#.VuFHCvnhC70</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1517/13543776.2015.1056737" target="_blank" >10.1517/13543776.2015.1056737</a>
Alternative languages
Result language
angličtina
Original language name
Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Original language description
Introduction: Deubiquitinating-enzymes (DUBs) are key components of the ubiquitin-proteasome system (UPS). The fundamental role of DUBs is specific removal of ubiquitin from substrates. DUBs contribute to activation/deactivation, recycling and localization of numerous regulatory proteins, and thus play major roles in diverse cellular processes. Altered DUB activity is associated with a multitudes of pathologies including cancer. Therefore, DUBs represent novel candidates for target-directed drug development.Areas covered: The article is a thorough review/accounting of patented compounds targeting DUBs and stratifying/classifying the patented compounds based on: chemical-structures, nucleic-acid compositions, modes-of-action, and targeting sites. The review provides a brief background on the UPS and the involvement of DUBs. Furthermore, methods for assessing efficacy and potential pharmacological utility of DUB inhibitor (DUBi) are discussed.Expert opinion: The FDA's approval of the 20S
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Opinion on Therapeutic Patents
ISSN
1354-3776
e-ISSN
—
Volume of the periodical
25
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
18
Pages from-to
1191-1208
UT code for WoS article
000369387300002
EID of the result in the Scopus database
—